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Chemotherapy regimens for early stage breast cancer have been tested by randomized clinical
trials, and specified by evidence-based practice guidelines. However, little is known about the
translation of trial results and guidelines to clinical practice. We extracted individual-level data on
chemotherapy administration from the electronic medical records of Kaiser Permanente Northern
California (KPNC), a pre-paid integrated healthcare system serving 29% of the local population.
We linked data to the California Cancer Registry, incorporating socio-demographic and tumor
factors, and performed multivariable logistic regression analyses on the receipt of specific
chemotherapy regimens. We identified 6,004 women diagnosed with Stage I–III breast cancer at
KPNC during 2004–2007; 2,669 (44.5 %) received at least one chemotherapy infusion at KPNC
within 12 months of diagnosis. Factors associated with receiving chemotherapy included age <50
years [odds ratio (OR) 2.27, 95 % confidence interval (CI) 1.81–2.86], tumor >2 cm (OR 2.14, 95
% CI 1.75-2.61), involved lymph nodes (OR 11.3, 95 % CI 9.29–13.6), hormone receptor-negative
(OR 6.94, 95% CI 4.89–9.86), Her2/neu-positive (OR 2.71, 95% CI 2.10–3.51), or high grade (OR
3.53, 95 % CI 2.77-4.49) tumors; comorbidities associated inversely with chemotherapy use [heart
disease for anthracyclines (OR 0.24, 95 % CI 0.14–0.41), neuropathy for taxanes (OR 0.45, 95 %
CI 0.22–0.89)]. Relative to high-socioeconomic status (SES) non-Hispanic Whites, we observed
less anthracycline and taxane use by SES non-Hispanic Whites (OR 0.63, 95 % CI 0.49-0.82) and
American Indians (OR 0.23, 95 % CI 0.06–0.93), and more anthracycline use by high-SES Asians/
Pacific Islanders (OR 1.72, 95 % CI 1.02–2.90). In this equal-access healthcare system,
chemotherapy use followed practice guidelines, but varied by race and socio-demographic factors.
These findings may inform efforts to optimize quality in breast cancer care.
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Introduction
Breast cancer is the most common non-cutaneous malignancy of women in the United States
(U.S.), and survivors comprise approximately 2% of the population [1]. The high incidence
of breast cancer has facilitated large randomized clinical trials, generations of which have
defined effective adjuvant chemotherapy regimens for Stage I–III disease [2–6]. Evidence-
based practice guidelines and quality measures have translated clinical trial results into
recommendations about chemotherapy agents, doses and schedules, based on patient and
tumor characteristics [7, 8]. However, considerable uncertainty remains as to how research
findings and guidelines are applied outside of clinical trials, the setting in which the great
majority of patients are treated [9–12].
Barriers to population-based studies of chemotherapy use include lack of treatment detail
and under-reporting. Population-based cancer registries such as the Surveillance,
Epidemiology and End Results (SEER) program record chemotherapy as part of the first
course of treatment, but details such as drug combinations, schedules and number of cycles
—all of which have been demonstrated to impact cancer recurrence and survival in clinical
trials [5, 6, 13, 14]—are unavailable. Moreover, administration of chemotherapy appears
under-reported in registry data [15, 16]. Studies using linkage to Medicare claims are limited
to adults aged 65 years or older, and based on claims data rather than actual drug
administrations. To overcome these limitations, we linked chemotherapy administration data
from the electronic medical records (EMR) of Kaiser Permanente Northern California
(KPNC, a participant in the National Cancer Institute's Cancer Research Network) [17] with
the California Cancer Registry (CCR) database; members comprise nearly one-third of the
local population, and are representative in terms of race/ethnicity and socioeconomic status
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(SES). To determine how evidence-based guidelines disseminate into cancer care across the
population, we analyzed factors associated with adjuvant chemotherapy use in Stage I–III
breast cancer patients diagnosed from 2004 to 2007.
Methods
Data sources and linkage
The KPNC coverage area includes 23 counties in the San Francisco Bay Area and the
Central Valley of California, from Sacramento to Fresno. We used two chemotherapy
administration data repositories from KPNC: the Case Management for Medical Oncology
with Laboratory and Outcome Tracking (CAMMOLOT) database, initiated in 1998, and the
Clinical Oncology Pharmacy System (COPS) database, initiated in 1999. KPNC pharmacy
records were used to identify filled prescriptions for endocrine therapy of breast cancer,
including tamoxifen and aromatase inhibitors.[18] We used KPNC data on diagnoses
associated with inpatient and outpatient encounters to identify specific comorbidities present
from 12 months before to one month after diagnosis, and likely to influence chemotherapy
selection, including heart disease (ICD-9 codes 410.0–410.9, 428.0–428.9, 411.0–411.9,
413.0–413.9, 394.0–396.9, 424.0–424.9, 425.0–425.9), diabetes (ICD-9 codes 250.0–250.9),
and neuropathy (ICD-9 codes 356.0–357.9, 250.6, 249.6, 337.0). In addition, we used a
modified Charlson Comorbidity Index to measure the burden of other serious comorbities;
this weighted score includes conditions found in the original Charlson Index including liver
disease, cerebrovascular disease, and acquired immune deficiency syndrome, among others
[19–22].
Comprising three registries (Greater Bay Area, Los Angeles, and Greater California) within
the SEER program, the CCR is a population-based registry which has collected data about
all primary cancers diagnosed among California residents since 1988. Demographic and
tumor information is abstracted from medical records according to standard protocols [23].
CCR data have been described [24], and include age and marital status at diagnosis, race/
ethnicity, tumor size, presence of lymph node involvement, cancer stage according to the
American Joint Committee on Cancer [25], tumor grade, histology, laterality, focality,
expression of estrogen receptor (ER), progesterone receptor (PR) and Her2/neu (HER2),
other cancer treatments including surgery and radiation, and vital status at the time of last
contact or vital status record linkage. For this cohort, most clinical information is derived
from the KPNC cancer registry; however, CCR data may incorporate additional reports from
facilities outside KPNC. We included information on distance between a patient's address
and the KPNC facility reporting her diagnosis [26], and on neighborhood (block group-
level) SES, using a previously developed index that combines Census 2000 measures of
education, income, occupation and housing characteristics [27].
KPNC records over 1999–2007 were extracted for linkage to CCR tumor-level data. KPNC
chemotherapy infusion databases became fully implemented in 2004; therefore, we
restricted analyses to 2004–2007. Infusion data were limited to 12 months following
diagnosis to maximize capture of chemotherapy used in the post-surgical adjuvant setting,
while minimizing capture of chemotherapy administered for cancer recurrence. Analyses
were approved by the Institutional Review Boards of the state of California, the Cancer
Prevention Institute of California, and KPNC Division of Research.
Chemotherapy data extraction and coding
We extracted data on drug names, infusion dates, and number of infusions. We focused on
two of the most active drug classes for breast cancer, anthracyclines and taxanes [5, 8, 13,
14, 28]; for comparison, we evaluated the older cyclophosphamide, methotrexate, and 5-
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flurouracil (CMF) regimen [29, 30]. We also assessed use of the monoclonal antibody
trastuzumab (Herceptin), which was FDA-approved for adjuvant treatment of Stage I–III
HER2-positive breast cancer in 2006 [31, 32]. We defined cycles according to the number of
drug infusions, with cycle length defined according to practice guidelines [5, 8, 13, 14, 28].
Statistical analysis
We used exploratory multivariable logistic regression to model the association of clinical
and socio-demographic factors with treatment. We included age, race/ethnicity,
neighborhood SES, and ER/PR in all models because these variables were of interest a
priori, and then used stepwise selection to select other significant covariates among tumor
size, histology, grade, lymph node involvement, laterality, HER2 status, marital status,
distance to reporting KPNC facility, diabetes, heart disease, neuropathy, modified Charlson
Comorbidity Index, multiple breast tumors, endocrine therapy, and surgery type for
inclusion in the final model. Because of high correlations among variables, two combined
variables were modeled: receipt of endocrine therapy and ER/PR status, and race/ethnicity
and neighborhood SES. To control for changes in guidelines over time, year of diagnosis
was included as a continuous variable. Analyses were conducted using SAS, Version 9.3
(SAS Institute, Cary, NC).
Outcomes of multivariable analyses included receipt of (1) any chemotherapy, (2) at least
four cycles (defined as infusions at least 1-week apart) of an anthracycline (doxorubicin or
epirubicin), (3) at least four cycles of a taxane (docetaxel or paclitaxel), (4) at least four
cycles of an anthracycline plus at least four cycles of a taxane, (5) at least four cycles of an
anthracycline and taxane compared to at least six cycles of CMF. For analyses 1–4, each
outcome was compared to receiving any other chemotherapy (fewer cycles of the drug/s of
interest, or any other drugs), a comparison we chose to estimate the odds of receiving
particular chemotherapy drugs, compared to other drugs. We selected a threshold of four
cycles because it was the minimum number for all regimens recommended by practice
guidelines [8]. We also examined two measures of the Quality Oncology Practice Initiative
(QOPI) of the American Society of Clinical Oncology (ASCO) [7], which we chose for their
feasibility with available data: receipt of at least one cycle of combination chemotherapy
within 4 months of diagnosis by women age <70 years with ER/PR-negative tumors of size
≥1 cm (cm), and receipt of trastuzumab by women with HER2-positive tumors, compared in
each analysis to eligible women who did not receive the specified regimen. We restricted the
trastuzumab analysis to 2006–2007, because adjuvant trastuzumab was not FDA-approved
until 2006 [31, 32].
Results
Patient characteristics
We identified 6,004 women who were residents of California and diagnosed with a first
primary, Stage I–III breast cancer at KPNC from 2004 to 2007 (Table 1; Fig. 1). Twenty-
one percent was younger than 50 years of age; 52.9 % were age 50–69, and 25.9 % were age
≥70. The majority (68.3 %) was non-Hispanic (NH) White, in the top two state-wide SES
quintiles (64 %), and married (59.1 %). The majority had tumors <2 cm (58.2 %), without
lymph node involvement (68.9 %) and Stage I (52.8 %). Most tumors expressed ER and/or
PR (81.3 %); HER2 amplification or over-expression was present in 11.3 %, unknown or
borderline in 23.5 %; HER2 status was based on SEER data, with missing rates as
previously reported [24, 33, 34]. Diabetes was present in 11.3 %, neuropathy in 3.1 %, and
heart disease in 7.2 %. KPNC recorded endocrine therapy in 85.5 % of patients with ER/PR-
positive cancer; 38.9 % of all patients underwent mastectomy, 59.5 % breast conserving
surgery, and 50.4 % radiation therapy. In total, 2,669 women (44.5 %) received at least one
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infusion of chemotherapy at a KPNC facility. There was 96.5 % agreement between CCR
and KPNC on chemotherapy records: KPNC missed 2.62 % of patients who received
chemotherapy, and CCR missed 4.01 %.
Any chemotherapy
Odds of receiving chemotherapy were greater among women who were younger [age <40,
odds ratio (OR) 4.45, 95 % confidence interval (CI) 2.73–7.26], had tumors ≥2 cm (OR ≥
2.14, 95 % CI 1.75–2.61), involved lymph nodes (OR 11.3, 95 % CI 9.29–13.6), high grade
(OR 3.53, 95 % CI 2.77–4.49), ER/PR-negative (OR 6.94, 95 % CI 4.89–9.86) or HER2-
positive (OR 2.71, 95 % CI 2.10–3.51) tumors, or received mastectomy (OR 1.41, 95 % CI
1.19–1.67). Chemotherapy was less used by women who were ≥70 years of age (OR 0.05,
95 % CI 0.04–0.07), unmarried (OR 0.8, 95 % CI 0.68–0.95), or had diabetes (0.71, 95% CI
0.54–0.94), neuropathy (OR 0.53, 95 % CI 0.31–0.89), heart disease (OR 0.38, 95 % CI
0.26–0.56), or a comorbidity index ≥3 (OR 0.03, 95 % CI 0.01–0.18, Table 2).
Anthracyclines and taxanes
Table 3 presents receipt of anthracyclines and taxanes. Use of at least four cycles of an
anthracycline, compared to any other chemotherapy, was more frequent among women who
were 40–49 years of age (OR 1.89, 95 % CI 1.30–2.75), high-SES Asians/Pacific Islanders
(OR 1.72, 95 % CI 1.02–2.90), or had involved lymph nodes (OR 2.14, 95 % CI 1.64–2.79).
Use of four or more cycles of an anthracycline was less frequent among women who were
age ≥70 (OR 0.18, 95 % CI 0.12–0.25), low-SES NH White (OR 0.65, 95 % CI 0.48–0.89),
had tumors <1 cm (OR 0.46, 95 % CI 0.29–0.73), positive HER2 (OR 0.58, 95 % CI 0.43–
0.82), or heart disease (OR 0.24, 95 % CI 0.14–0.41).
Receipt of at least four cycles of a taxane was more common among women who were age
<40 (OR 2.14, 95 % CI 1.45–3.17), had tumors ≥2 cm (OR 1.29, 95 % CI 1.03–1.63),
involved lymph nodes (OR 13.5, 95 % CI 10.9–16.6), high grade (OR 1.56, 95 % CI 1.10–
2.22), ER/PR-negative (OR 1.44, 95 % CI 1.13–1.84) or HER2-positive (OR 1.82, 95 % CI
1.39–2.37) tumors, multiple primary tumors (OR 2.33, 95 % CI 1.08–5.05), no or other
breast surgery (OR 4.32, 95 % CI 1.67–11.2) or later year of diagnosis (OR 1.10, 95 % CI
1.01–1.21). Taxanes were less used by women who were ≥70 years of age (OR 0.24, 95 %
CI 0.16–0.34), low-SES NH White (OR 0.66, 95 % CI 0.51–0.85), or had neuropathy (OR
0.45, 95% CI 0.22–0.89).
At least four cycles of anthracycline plus taxane was more likely among women who were
age <40 (OR 1.91, 95% CI 1.30–2.81), had tumors ≥2 cm (OR ≥1.39, 95 % CI 1.10–1.76),
involved lymph nodes (OR 12.9, 95 % CI 10.5–15.8), high grade (OR 1.71, 95% CI
1.20-2.42), ER/PR-negative (OR 1.29, 95 % CI 1.01–1.64), HER2-positive (OR 1.37, 95 %
CI 1.06–1.78), or multiple primary tumors (OR 2.54, 95% CI 1.19–5.45). Anthracyclines
plus taxanes were less likely among women who were ≥70 years of age (OR 0.25, 95% CI
0.17–0.36), low-SES NH Whites (OR 0.63, 95 % CI 0.49–0.82), low-SES AIAN, other, or
unknown ethnicity (OR 0.23, 95 % CI 0.06–0.93) had diabetes (OR 0.66, 95% CI 0.46–
0.94), or a comorbidity index of 1 (OR 0.65, 95 % CI 0.47–0.90).
Women were more likely to receive CMF, compared to an anthracycline plus taxane, if they
were ≥70 years of age (OR 22.8, 95 % CI 8.45–61.4), low-SES NH White (OR 2.79, 95 %
CI 1.25–6.23), had uninvolved lymph nodes (OR 27.5, 95 % CI 11.6–65.2), diabetes (OR
4.09, 95 % CI 1.59–10.5), or heart disease (OR 10.2, 95 % CI 3.64–28.6); they were less
likely to receive CMF, compared to an anthracycline plus taxane, if they had a tumor ≥2 cm
(OR 0.34, 95 % CI 0.17–0.69), positive HER2 (OR 0.16, 95 % CI 0.04–0.69), or a later
diagnosis year (OR 0.61, 95 % CI 0.41–0.92).
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Consistency with ASCO QOPI guidelines
Women age <70 with ER/PR-negative tumors of ≥1 cm were more likely to receive
combination chemotherapy within four months of diagnosis if they were 40–49 years of age
(OR 2.05, 95 % CI 1.16–3.62), had involved lymph nodes (OR 2.90, 95 % CI 1.77–4.57),
tumors ≥2 cm (OR 2.32, 95 % CI 1.38–3.90) or high grade (OR 4.26, 95 % CI 1.16–15.7);
this was less likely if they were 60–69 years of age (OR 0.61, 95 % CI 0.38–0.98), high SES
Asian or Black (OR 0.47, 95 % CI 0.23–0.97 and 0.37, 95 % CI 0.16–0.86, respectively),
had neuropathy (OR 0.35, 95 % CI 0.13–0.98), or a comorbidity index of ≥3 (OR 0.05, 95 %
CI 0.00–0.58). Women with HER2-positive tumors were more likely to receive trastuzumab
if they were <40 years of age (OR 10.9, 95 % CI 1.51–79.3), had involved lymph nodes (OR
3.67, 95 % CI 1.66–8.12), high grade (OR 6.46, 95% CI 1.72–24.2) or ER/PR-negative (OR
2.99, 95 % CI 1.36–6.57) tumors. Trastuzumab was less used by women who were ≥70
years of age (OR 0.03, 95 % CI 0.01–0.10) or had tumors <1 cm (OR 0.17, 95 % CI 0.06–
0.47) (Table 4).
Discussion
To our knowledge, this is the first use of linked electronic drug administration records and
SEER registry data for a detailed analysis of breast cancer chemotherapy; this linkage
provides a more complete picture than either source alone. Leveraging high-quality EMR
data available through a large, integrated health care system covering a diverse yet
representative population, we observed more chemotherapy use by women with adverse
prognostic factors (including young age, large tumor size, and involved lymph nodes), and
less chemotherapy use by women at higher risk for drug-specific toxicities, given their
comorbidities (including heart disease for anthracyclines, and neuropathy for taxanes); these
patterns follow clinical trial results and practice guidelines. However, we found variations in
specific drug use according to race/ethnicity and SES; compared to high-SES NH Whites,
there was less receipt of highly active anthracycline- and taxane-based regimens by low-SES
NH Whites and American Indian/Alaskan Natives (AIAN), and more receipt of
anthracyclines by high-SES Asians/Pacific Islanders (API). High-SES Blacks and API were
less likely than high-SES NH Whites to receive timely combination chemotherapy for ER/
PR-negative cancer. This variability occurred despite the equal-access care setting, and
warrants further study of cultural and socio-demographic influences on cancer care.
Given the coverage structure, KPNC patients are unlikely to seek out-of-network care,
which reduces the chance that we missed records of chemotherapy administered at other
institutions; only 2.6 % of patients were coded by CCR, but not by KPNC, as having had
chemotherapy. Moreover, all KPNC patients have health insurance, reducing variability in
access. This study thus offers a nearly complete picture of chemotherapy use in a large,
diverse healthcare system [17, 35, 36]. Predictably, most care followed results of clinical
trials, particularly those reporting that women with younger age, larger tumor size, involved
lymph nodes, higher grade, positive HER2 and negative ER/PR status derive greater benefit
from chemotherapy [2–5, 31, 32]. Relevant practice guidelines include those of the National
Comprehensive Cancer Network and St. Gallen Consensus Conference [8, 37]; these lengthy
documents incorporate nuances of decision making, including patient preferences, about
which we lacked information. Thus, we focused on the ASCO QOPI measures, which
establish common ground for quality care [7]. Even though QOPI guidelines were not
formalized until 2010 [7], we observed high concordance (88.8–92.5%) with two QOPI
measures which we could assess using available data, for women with ER/PR-negative and
HER2-positive tumors. We found evidence of a switch from the older CMF regimen to
newer “third generation” anthracycline and taxane-based combinations over time, consistent
with emerging randomized trials and evidence summaries during this period [5, 13, 38–41].
Our finding of less anthracycline use by women with heart disease, less taxane use by
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women with neuropathy, and less combination chemotherapy among women with diabetes
or more comorbidities, likely reflects appropriate patient-level tailoring of care.
KPNC members are representative of the general population, allowing us to evaluate
chemotherapy use by socio-demographic characteristics [42, 43]. Our findings of less
chemotherapy use among unmarried women, and less anthracycline and taxane use by low-
SES NH Whites and NH AIANs, may result from limited social or financial resources with
which to offset the burden of chemotherapy. Prior studies have investigated breast cancer
treatment across diverse populations [44–50], with recent work reporting an interplay of race
and marital status [51], interactions between race and tumor subtype within clinical trials
[52], and a lower probability of guideline-consistent care among patients with less insurance
coverage [53]. A novel contribution of our work is its consideration of specific
chemotherapy agents and combinations, which may shed light on observed patterns of care;
for example, our finding of more anthracycline use among high-SES APIs compared to
high-SES NH Whites might reflect differences in education, body mass index, or lifestyle,
which could mitigate concerns about the cardiac side effects of this drug class. Conversely,
we observed lower odds of receiving timely combination chemotherapy for ER/PR-negative
cancers (an ASCO QOPI measure) among high-SES APIs and Blacks compared to high-
SES NH Whites, a finding which warrants investigation of potential barriers to treatment
initiation.
Although these associations control for temporal trends, tumor prognostic factors, age, and
comorbidities, they cannot unravel the complexity of applying trial results and practice
guidelines to the care of an individual, a therapeutic process that is enmeshed with the goals,
fears, and experiences of both physician and patient. Further study of the factors that guide
decisions about cancer treatment might clarify the socio-demographic use patterns that we
observed.
Our study has some limitations. We extracted individual drug names and infusion patterns
from KPNC administrative data, an approach validated by a recent study of the Cancer
Research Network [54]; however, we did not evaluate treatment delays, deviations from
standard dosing by body surface area or other parameters, use of ancillary medications (such
as hematopoietic growth factors and bisphosphonates) or novel diagnostics which may be
used to target chemotherapy (such as tumor genomic profiling for recurrence risk). These
questions are key priorities for future research. We were particularly interested in examining
racial/ethnic and SES interactions; however, our significant findings should be interpreted
with caution given the number of race/ethnicity by SES combinations, small numbers in
some groups, and potential for chance findings.
Many of the above questions are not amenable to investigation by currently available
databases. However, KPNC has recently implemented the Beacon infusion medication
module for its Epic™ (Verona, WI)-based electronic medical record that replaces the stand-
alone CAMMOLOT and COPS databases. This database will facilitate future investigation
of these questions as it provides substantially greater detail on infusion medication planning
and administration.
We used EMRs to study patterns of chemotherapy treatment for breast cancer in a large,
diverse medical care program from 2004 to 2007. We observed care patterns consistent with
practice guidelines, including more chemotherapy use by women having the most to gain
from it, given their adverse prognostic factors, and less chemotherapy use by women with
comorbidities that increased risk for drug-specific toxicities. However, we also observed
significant variability according to race and socio-demographic factors, despite the equal-
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access setting. These results may inform efforts to optimize treatment for all patients, and
guide future studies of quality in breast cancer care.
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Flow chart of case inclusion for multivariable analysis of a receipt of any chemotherapy, of
anthracyclines plus taxanes, and of cyclophosphamide, methotrexate, and 5-flurouracil
(CMF) and b American Society of Clinical Oncology Quality Oncology Practice Initiative
measures: receipt of combination chemotherapy within 4 months of diagnosis by women
aged <70 years having estrogen and progesterone receptor-negative tumors ≥1 centimeter,
and receipt of trastuzumab by women having HER2-positive tumors
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Table 2
Multivariable analysis of receiving any chemotherapy versus no chemotherapy, Stage I–
III breast cancer patients, Kaiser Permanente Northern California (KPNC), 2004–2007
(N = 6004)
Odds ratio 95 % CI
Age (years)
 ≤39 4.45 2.73–7.26
 40–49 2.27 1.81–2.86
 50–59 1.0
 60–69 0.39 0.32–0.48
 ≥70 0.05 0.04–0.07
Race, socio-economic status (SES)
 High SES Non-Hispanic (NH) White 1.0
 High SES Hispanic 1.25 0.89–1.75
 High SES NH American Indian, Alaskan Native, other, or unknown (AIAN 0.48 0.16–1.47
 High SES NH Asian or Pacific Islander (API 0.92 0.70–1.21
 High SES NH Black 1.08 0.67–1.74
 Low SES NH White 0.84 0.68–1.03
 Low SES Hispanic 1.06 0.73–1.52
 Low SES NH AIAN 0.65 0.23–1.86
 Low SES API 0.98 0.64–1.48
 Low SES NH Black 0.98 0.67–1.44
Marital status
 Married 1.0
 Unmarried (single, separated, divorced, widowed 0.80 0.68–0.95
 Unknown 0.51 0.22–1.23
Tumor size (cm)
 <1 cm 0.24 0.19–0.31
 1 to <2 1.0
 2 to <3 2.14 1.75–2.61
 3 to <4 3.02 2.26–4.05
 4 to <5 4.27 2.74–6.64
 ≥5 2.89 1.77–4.72
 Microscopic foci, diffuse, or unknown 0.17 0.10–0.28
Lymph node involvement
 Negative or unknown 1.0
 Positive 11.3 9.29–13.6
Grade
 Grade I (well differentiated) 1.0
 Grade II (moderately differentiated) 2.06 1.66–2.55
 Grade III (poorly or undifferentiated 3.53 2.77–4.49
 Unknown 1.49 1.07–2.09
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Odds ratio 95 % CI
Estrogen, progesterone receptors (ER/PR) and endocrine therapya
 ER/PR-positive, no endocrine therapy 1.0
 ER/PR-negative, no endocrine therapy 6.94 4.89–9.86
 ER/PR-unknown, no endocrine therapy 0.20 0.06–0.75
 ER/PR-positive, received endocrine therapy 2.31 1.71–3.13
HER2
 Negative 1.0
 Positive 2.71 2.10–3.51
 Unknown or borderline 1.38 1.14–1.67
Diabetes
 No 1.0
 Yes 0.71 0.54–0.94
Neuropathy
 No 1.0
 Yes 0.53 0.31–0.89
Heart disease
 No 1.0
 Yes 0.38 0.26–0.56
Modified Charlson Comorbidity Indexb
 0 1.0
 1 1.12 0.86–1.45
 2 1.10 0.55–2.20
 ≥3 0.03 0.01–0.18
Distance to reporting KPNC facility (miles)
 <5 1.0
 5 to <10 1.05 0.87–1.27
 10 to <15 0.93 0.73–1.20
 15 to <20 1.31 0.99–1.74
 20 to <30 0.89 0.65–1.22
 30 to <40 0.57 0.33–0.97
 ≥40 1.15 0.63–2.09
Surgery type
 Breast conserving surgery 1.0
 Mastectomy 1.41 1.19–1.67
 None or other 0.72 0.37–1.39
Year of diagnosis, per year 1.03 0.96–1.12
a
Excluded ER/PR-negative or unknown, received endocrine therapy, given the high probability that these groups reflect errors in data collection,
since endocrine therapy is not clinically indicated in this setting
b
This Charlson Comorbidity Index excluded heart disease, diabetes and neuropathy, which were evaluated separately
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Table 4
Multivariable analysis of American Society of Clinical Oncology Quality Oncology
Practice Initiative measures, Stage I–III breast cancer patients, Kaiser Permanente
Northern California, 2004–2007
Combination chemotherapy within 4 months
of diagnosis, if estrogen and progesterone
receptor-negative, size ≥ 1 cm and age <70
years (N = 725)
Trastuzumab if HER2-positive, 2006–
2007a (N = 287)
OR 95 % CI OR 95 % CI
Age years
 ≤39 2.62 0.88–7.85 10.9 1.51–79.3
 40–49 2.05 1.16–3.62 0.63 0.24–1.65
 50–59 1.0 1.0
 60–69 0.61 0.38–0.98 0.41 0.16–1.04
 ≥70 NA b 0.03 0.01–0.10
Race, socio-economic status (SES)
 High SES NH White 1.0 1.0
 High SES Hispanic 1.09 0.41–2.87 1.32 0.34–5.13
 High SES NH Asian or Pacific Islander (API) 0.47 0.23–0.97 0.79 0.27–2.31
 High SES NH Black 0.37 0.16–0.86 2.54 0.45–14.5
 Low SES NH White 0.63 0.35–1.11 1.47 0.53–4.09
 Low SES Hispanic 0.69 0.30–1.59 0.87 0.21–3.63
 Low SES API 0.54 0.20–1.48 0.49 0.12–2.05
 Low SES NH Black 0.50 0.25–1.03 1.89 0.38–9.33
Tumor size (cm)
 <1 NA b 0.17 0.06–0.47
 1 to <2 1.0 1.0
 2 to <3 2.32 1.38–3.90 1.27 0.52–3.10
 3 to <4 1.46 0.81–2.63 2.60 0.79–8.62
 4 to <5 2.18 0.86–5.51 2.55 0.30–22.0
 ≥5 1.11 0.41–3.00 2.91 0.44–19.5
 Microscopic foci, diffuse, or unknown NA b 0.24 0.01–4.05
Lymph node involvement
 Negative or unknown 1.0 1.0
 Positive 2.90 1.77–4.57 3.67 1.66–8.12
Grade
 Grade I 1.0 1.0
 Grade II 4.13 1.06–16.1 5.05 1.38–18.5
 Grade III 4.26 1.16–15.7 6.46 1.72–24.2
 Unknown 1.91 0.24–15.3
Estrogen, Progesterone Receptors
 Positive (either or both) NA b 1.0
 Negative (both) 2.99 1.36–6.57
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Combination chemotherapy within 4 months
of diagnosis, if estrogen and progesterone
receptor-negative, size ≥ 1 cm and age <70
years (N = 725)
Trastuzumab if HER2-positive, 2006–
2007a (N = 287)
OR 95 % CI OR 95 % CI
Neuropathy
 No 1.0 NA b
 Yes 0.35 0.13–0.98
Modified Charlson Comorbidity Indexc
 0 1.0 NA b
 1 1.32 0.61–2.85
 2 1.35 0.13–13.9
≤3 0.05 0.00–0.58
Year of diagnosis (per year) 1.01 0.83–1.23 1.86 0.90–3.86
a
This analysis was limited to the years 2006–2007, because trastuzumab was not recommended for Stage I–III breast cancer prior to that time
b
Not applicable; this variable was not included in the final multivariable model
c
This Charlson Comorbidity Index excluded heart disease, diabetes and neuropathy, since they are separate variables
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